The Pharmacovigilance Risk Assessment Committee (PRAC) met on 9-12 February 2026. The PRAC recommends the withdrawal of marketing authorizations for medicinal products containing levamisole. Leukoencephalopathy has been confirmed as a serious side effect of levamisole. The EMA Safety Committee has assessed this safety signal. A safety signal is information indicating a new potentially causal connection or a new aspect of a known association. The meeting included an assessment of the safety signals of levamisole drugs. The related PRAC statistics for February 2026 have been published.